The combination of the antiestrogen endoxifen with all-trans-retinoic acid has anti-proliferative and anti-migration effects on melanoma cells without inducing significant toxicity in non-neoplasic cells

European Journal of Pharmacology

Volumn 715, Issue 1-3, 2013, Pages 354-362

  Ribeiro, Mariana P C ^a,b   Silva, Filomena S G ^a,b   Paixão, Joana ^a,b   Santos, Armanda E ^a,b   Custódio, José B A ^a,b  

^a UNIVERSITY OF COIMBRA   (Portugal)

^b UNIVERSITY OF COIMBRA   (Portugal)

Author keywords

All trans retinoic acid; Endoxifen; Melanoma; Migration; Proliferation; Tamoxifen

Indexed keywords

ANTIESTROGEN; ENDOXIFEN; RETINOIC ACID; TAMOXIFEN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BIOENERGY; BIOMASS; CANCER INHIBITION; CELL CYCLE PROGRESSION; CELL DEATH; CELL FUNCTION; CELL MIGRATION; CELL VIABILITY; CONTROLLED STUDY; DNA SYNTHESIS; DRUG CYTOTOXICITY; DRUG EFFICACY; FEMALE; MALE; MELANOMA; MELANOMA CELL; MIGRATION INHIBITION; MITOCHONDRION; NONHUMAN; PRIORITY JOURNAL; RAT; TREATMENT OUTCOME;

ALL-TRANS-RETINOIC ACID; ENDOXIFEN; MELANOMA; MIGRATION; PROLIFERATION; TAMOXIFEN;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; ENERGY METABOLISM; ESTROGEN RECEPTOR MODULATORS; FEMALE; LIVER; MALE; MELANOMA; MICE; MITOCHONDRIA; RATS; TAMOXIFEN; TRETINOIN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84885471345     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2013.04.038     Document Type: Article

References (49)

1. Ahmad, A., Shahabuddin, S., Sheikh, S., Kale, P., Krishnappa, M., Rane, R.C., Ahmad, I., 2010. Endoxifen, a new cornerstone of breast cancer therapy: demonstration of safety, tolerability, and systemic bioavailability in healthy human subjects. Clin. Pharmacol. Ther. 88, 814-817.
2. Beguerie, J.R., Xingzhong, J., Valdez, R.P., 2010. Tamoxifen vs. non-tamoxifen treatment for advanced melanoma: a meta-analysis. Int. J. Dermatol. 49, 1194-1202.
3. Boskovic, G., Desai, D., Niles, R.M., 2002. Regulation of retinoic acid receptor alpha by protein kinase C in B16 mouse melanoma cells. J. Biol. Chem. 277, 26113-26119. (Pubitemid 34967095)
4. Budd, G.T., Adamson, P.C., Gupta, M., Homayoun, P., Sandstrom, S.K., Murphy, R.F., McLain, D., Tuason, L., Peereboom, D., Bukowski, R.M., Ganapathi, R., 1998. Phase I/II trial of all-trans retinoic acid and tamoxifen in patients with advanced breast cancer. Clin. Cancer Res. 4, 635-642. (Pubitemid 28193562)
5. Bushue, N., Wan, Y.J., 2010. Retinoid pathway and cancer therapeutics. Adv. Drug Deliv. Rev. 62, 1285-1298.
6. Cardoso, C.M.P., Custódio, J.B.A., Almeida, L.M., Moreno, A.J.M., 2001. Mechanisms of tamoxifen deleterious effects on the respiration rate and phosphorylation efficiency of mitochondria. Toxicol. Appl. Pharmacol. 176, 145-152. (Pubitemid 34001304)
7. Carmo, A., Carvalheiro, H., Crespo, I., Nunes, I., Lopes, M.C., 2011. Effect of temozolomide on the U-118 glioma cell line. Oncol. Lett. 2, 1165-1170.
8. Chakravarti, N., Lotan, R., Diwan, A.H., Warneke, C.L., Johnson, M.M., Prieto, V.G., 2007. Decreased expression of retinoid receptors in melanoma: entailment in tumorigenesis and prognosis. Clin. Cancer Res. 13, 4817-4824. (Pubitemid 47294789)
9. Cohen, C., DeRose, P.B., Campbell, W.G., Schlosnagle, D.C., Sgoutas, D., 1990. Estrogen receptor status in malignant melanoma. Am. J. Dermatopathol. 12, 562-564.
10. 2+ and inorganic phosphate. Toxicol. Appl. Pharmacol. 152, 10-17. (Pubitemid 28498668)
11. Danforth, D.N., 2004. All trans-retinoic acid acts synergistically with hydroxyta-moxifen and transforming-growth factor beta to stimulate apoptosis in MCF-7 breast cancer cells. J. Endocrinol. 183, 395-404.
12. Drewa, G., Schachtshhabel, D.O., 1985. Influence of retinoids on growth and melanin content of Harding-Passay melanoma cells in vitro and B16 transplan-table melanoma in vivo. Arch. Geschwulstforsch 55, 93-98. (Pubitemid 15109797)
13. Eto, I., 2010. Upstream molecular signaling pathways of p27 (Kip1) expression: effects of 4-hydroxytamoxifen, dexamethasone, and retinoic acids. Cancer Cell Int. 10, 3.
14. Fan, J., Eastham, L., Varney, M.E., Hall, A., Adkins, N.L., Chetel, L., Sollars, V.E., Georgel, P., Niles, R.M., 2010. Silencing and re-expression of retinoic acid receptor beta2 in human melanoma. Pigment Cell Melanoma Res 23, 419-429.
15. Fisher, R.I., Neifeld, J.P., Lippman, M.E., 1976. Oestrogen receptors in human malignant melanoma. Lancet 2, 337-339.
16. Flowers, J.L., Seigler, H.F., McCarty Sr., K.S., Konrath, J., McCarty Jr., K.S., 1987. Absence of estrogen receptor in human melanoma as evaluated by a monoclonal antiestrogen receptor antibody. Arch. Dermatol. 123, 764-765. (Pubitemid 17076169)
17. Gornall, A.G., Bardawill, C.J., David, M.M., 1949. Determination of serum proteins by means of the biuretic reaction. J. Biol. Chem. 177, 751-766.
18. Helige, C., Smolle, J., Zellnig, G., Hartmann, E., Fink-Puches, R., Kerl, H., and Tritthart., H. A., 1993. Inhibition of K1735-M2 melanoma cell invasion in vitro by retinoic acid. Clin. Exp. Metastasis 11, 409-418. (Pubitemid 23285494)
19. Holy, J., Lamont, G., Perkins, E., 2006. Disruption of nucleocytoplasmic trafficking of cyclin D1 and topoisomerase II by sanguinarine. BMC Cell Biol. 7, 13.
20. Houben, R., Ortmann, S., Drasche, A., Troppmair, J., Herold, M.J., Becker, J.C., 2009. Proliferation arrest in B-Raf mutant melanoma cell lines upon MAPK pathway activation. J. Invest. Dermatol. 129, 406-414.
21. Hua, S., Kittler, R., White, K.P., 2009. Genomic antagonism between retinoic acid and estrogen signaling in breast cancer. Cell 137, 1259-1271.
22. Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., Thun, M.J., 2009. Cancer statistics, 2009. CA Cancer J. Clin. 59, 225-249.
23. Kanter-Lewensohn, L., Girnita, L., Girnita, A., Dricu, A., Olsson, G., Leech, L., Nilsson, G., Hilding, A., Wejde, J., Brismar, K., Larsson, O., 2000. Tamoxifen-induced cell death in malignant melanoma cells: possible involvement of the insulin-like growth factor-1 (IGF-1) pathway. Mol. Cell Endocrinol. 16, 131-137. (Pubitemid 30625191)
24. Kelly, C.M., Juurlink, D.N., Gomes, T., Duong-Hua, M., Pritchard, K.I., Austin, P.C., Paszat, L.F., 2010. Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. B.M. J 340, c693.
25. Kiyotani, K., Mushiroda, T., Nakamura, Y., Zembutsu, H., 2012. Pharmacogenomics of tamoxifen: roles of drug metabolizing enzymes and transporters. Drug Metab. Pharmacokinet. 27, 122-131.
26. Ko, J.M., Fisher, D.E., 2011. A new era: melanoma genetics and therapeutics. J. Pathol. 223, 241-250.
27. Koay, D.C., Zerillo, C., Narayan, M., Harris, L.N., DiGiovanna, M.P., 2010. Anti-tumor effects of retinoids combined with trastuzumab or tamoxifen in breast cancer cells: induction of apoptosis by retinoid/trastuzumab combinations. Breast Cancer Res. 12, R62.
28. Lammers, L.A., Mathijssen, R.H., van Gelder, T., Bijl, M.J., de Graan, A.J., Seynaeve, C., van Fessem, M.A., Berns, E.M., Vulto, A.G., van Schaik, R.H., 2010. The impact of CYP2D6-predicted phenotype on tamoxifen treatment outcome in patients with metastatic breast cancer. Br. J. Cancer 103, 765-777.
29. Lecavalier, M.A., From, L., Gaid, N., 1990. Absence of estrogen receptors in dysplastic nevi and malignant melanoma. J. Am. Acad. Dermatol. 23, 242-246. (Pubitemid 20259917)
30. Liang, C.C., Park, A.Y., Guan, J.L., 2007. In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nat. Protoc. 2, 329-333. (Pubitemid 47040047)
31. Lim, Y.C., Desta, Z., Flockhart, D.A., Skaar, T.C., 2005. Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen. Cancer Chemother. Pharmacol. 55, 471-478. (Pubitemid 40568978)
32. Lotan, R., 1979. Different susceptibilities of human melanoma and breast carcinoma cell lines to retinoic acid-induced growth inhibition. Cancer Res. 39, 1014-1019. (Pubitemid 9135127)
33. Lu, W.J., Desta, Z., Flockhart, D.A., 2012. Tamoxifen metabolites as active inhibitors of aromatase in the treatment of breast cancer. Breast Cancer Res. Treat. 131, 473-481.
34. Matsuoka, H., Tsubaki, M., Yamazoe, Y., Ogaki, M., Satou, T., Itoh, T., Kusunoki, T., Nishida, S., 2009. Tamoxifen inhibits tumor cell invasion and metastasis in mouse melanoma through suppression of PKC/MEK/ERK and PKC/PI3K/Akt pathways. Exp. Cell Res. 315, 2022-2032.
35. Moreira, P.I., Custódio, J., Moreno, A., Oliveira, C.R., Santos, M.S., 2006. Tamoxifen and estradiol interact with the flavin mononucleotide site of complex i leading to mitochondrial failure. J. Biol. Chem. 281, 10143-10152. (Pubitemid 43864550)
36. Mori, T., Martinez, S.R., O'Day, S.J., Morton, D.L., Umetani, N., Kitago, M., Tanemura, A., Nguyen, S.L., Tran, A.N., Wang, H.J., Hoon, D.S., 2006. Estrogen receptor-alpha methylation predicts melanoma progression. Cancer Res. 66, 6692-6698. (Pubitemid 44085626)
37. Paixão, J., Dinis, T.C., Almeida, L.M., 2011. Dietary anthocyanins protect endothelial cells against peroxynitrite-induced mitochondrial apoptosis pathway and Bax nuclear translocation: an in vitro approach. Apoptosis 16, 976-989.
38. Ribeiro, M.P., Silva, F.S., Santos, A.E., Santos, M.S., Custódio, J.B., 2013. The antiestrogen endoxifen protects rat liver mitochondria from permeability transition pore opening and oxidative stress at concentrations that do not affect the phosphorylation efficiency. Toxicol. Appl. Pharmacol. 267, 104-122.
39. Ross-Innes, C.S., Stark, R., Holmes, K.A., Schmidt, D., Spyrou, C., Russell, R., Massie, C. E., Vowler, S.L., Eldridge, M., Carroll, J.S., 2010. Cooperative interaction between retinoic acid receptor-alpha and estrogen receptor in breast cancer. Genes Dev. 24, 171-182.
40. Rousseau, C., Pettersson, F., Couture, M.C., Paquin, A., Galipeau, J., Mader, S., Miller Jr., W.H., 2003. The N-terminal of the estrogen receptor (ERalpha) mediates transcriptional cross-talk with the retinoic acid receptor in human breast cancer cells. J. Steroid. Biochem. Mol. Biol. 86, 1-14. (Pubitemid 37025746)
41. Searovic, P., Alonso, M., Oses, C., Pereira-Flores, K., Velarde, V., Saez, C.G., 2009. Effect of tamoxifen and retinoic acid on bradykinin induced proliferation in MCF-7 cells. J. Cell Biochem. 106, 473-481.
42. Tang, X.H., Gudas, L.J., 2011. Retinoids, retinoic acid receptors, and cancer. Annu. Rev. Pathol. 6, 345-364.
43. Toma, S., Ugolini, D., Palumbo, R., 1999. Tamoxifen in the treatment of metastatic malignant melanoma: still a controversy? (Review). Int. J. Oncol. 15, 321-337.
44. Walker, M.J., Beattie, C.W., Patel, M.K., Ronan, S.M., Das Gupta, T.K., 1987. Estrogen receptor in malignant melanoma. J. Clin. Oncol. 5, 1256-1261.
45. Wilcken, N.R., Sarcevic, B., Musgrove, E.A., Sutherland, R.L., 1996. Differential effects of retinoids and antiestrogens on cell cycle progression and cell cycle regulatory genes in human breast cancer cells. Cell Growth Differ. 7, 65-74. (Pubitemid 26025484)
46. Wu, X., Hawse, J.R., Subramaniam, M., Goetz, M.P., Ingle, J.N., Spelsberg, T.C., 2009. The tamoxifen metabolite, endoxifen, is a potent antiestrogen that targets estrogen receptor alpha for degradation in breast cancer cells. Cancer Res. 69, 1722-1727.
47. Zhang, H., Satyamoorthy, K., Herlyn, M., Rosdahl, I., 2003. All-trans retinoic acid (at RA) differentially induces apoptosis in matched primary and metastaticme-lanoma cells - a speculation on damage effect of at RA via mitochondrial dysfunction and cell cycle redistribution. Carcinogenesis 24, 185-191. (Pubitemid 36267085)
48. Zhang, H., Rosdahl, I., 2004. Expression of p27 and MAPK proteins involved in alltrans retinoic acid-induced apoptosis and cell cycle arrest in matched primary and metastatic melanoma cells. Int. J. Oncol. 25, 1241-1248.
49. Zusi, F.C., Lorenzi, M.V., Vivat-Hannah, V., 2002. Selective retinoids and rexinoids in cancer therapy and chemoprevention. Drug Discov. Today 7, 1165-1174. (Pubitemid 35430153)